Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Miglioramento della mobilità dopo la rivascolarizzazione nella malattia delle arterie periferiche (IMPACT PAD)

30 settembre 2026 aggiornato da: Mary McDermott, Northwestern University

Migliorare la mobilità dopo la rivascolarizzazione nella malattia delle arterie periferiche: lo studio IMPACT PAD

Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.

Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity.

In a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

More than 300,000 surgical or endovascular lower extremity revascularization procedures are performed annually for Medicare beneficiaries who have lower extremity peripheral artery disease (PAD) without limb threatening ischemia, and rates of these procedures are increasing. In these patients, revascularization typically improves, but does not eliminate, PAD related walking impairment. Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.

Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity. A large body of evidence, assembled over more than 25 years, supports our hypothesis that inorganic nitrate (such as that in nitrate-rich beetroot juice) will improve walking performance and other lower extremity outcomes after lower extremity revascularization.

Effective, accessible, and safe therapies are needed to enhance the benefits and improve durability of lower extremity revascularization. Therefore, in a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2). In Secondary Aims, the trial will establish whether home-based exercise, compared to control, and whether nitrate-rich beetroot juice, compared to placebo, improve the Walking Impairment Questionnaire and the PROMIS Mobility Questionnaire and prevent hemodynamic failure of the revascularized vessel. In exploratory aims, the trial will test the effects of the interventions on plasma nitric oxide bioavailability. If our hypotheses are correct, results of this trial will have a major impact on improving mobility in the large and growing number of people undergoing revascularization for disabling PAD.

Tipo di studio

Interventistico

Iscrizione (Stimato)

386

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Arizona
      • Tucson, Arizona, Stati Uniti, 85724
        • Reclutamento
        • University of Arizona
        • Contatto:
          • Wei Zhou, MD
    • California
      • Downey, California, Stati Uniti, 90242
        • Reclutamento
        • Rancho Research Institute
        • Contatto:
          • Tze-Woei Tan, MD
    • Florida
      • Tampa, Florida, Stati Uniti, 33606
        • Reclutamento
        • University of South Florida
        • Contatto:
          • Ulka Sachdev, MD
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30307
        • Reclutamento
        • Emory University School of Medicine
        • Contatto:
          • Olamide Alabi, MD
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • Reclutamento
        • University of Chicago
        • Contatto:
          • Tamar Polonsky, MD
          • Numero di telefono: 773-702-6153
      • Chicago, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Northwestern University Feinberg School of Medicine
        • Investigatore principale:
          • Mary M McDermott, MD
        • Contatto:
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48202
        • Reclutamento
        • Henry Ford Health
        • Contatto:
          • Jonathan Ehrman, PhD
    • New Hampshire
      • Lebanon, New Hampshire, Stati Uniti, 03766
        • Reclutamento
        • Dartmouth Hitchcock Medical Center
        • Contatto:
          • Philip P Goodney, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

Successful lower extremity revascularization for disabling PAD performed at least 30 days before baseline testing and between 30 and 100 days before randomization.

Exclusion Criteria:

  1. History of leg amputation, not including toe and partial foot amputation
  2. Active gangrene
  3. Active limb threatening ischemia
  4. Already exercising at a level consistent with exercise intervention, using investigator discretion.
  5. Unstable angina
  6. Unwilling to drink study beverages
  7. Unwilling to adhere to the interventions and complete follow-up testing
  8. Currently taking sildenafil, tadalafil, or related drugs.
  9. Unwilling to accept randomization into either group (home-based exercise or attention control)
  10. Currently consuming beetroot juice, oral nitrate or nitrite, or a beetroot supplement and/or unwilling to avoid beetroot juice during the study. Participants will be asked to discontinue these items for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from taking these items, they will not be eligible for the clinical trial.
  11. History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial.
  12. Baseline blood pressure <100/45.
  13. Wheelchair confinement or requiring a walker to ambulate
  14. Walking is limited by a condition other than PAD
  15. Current foot ulcer
  16. Planned major surgery, coronary revascularization, or lower extremity revascularization during the next 12 months
  17. Major medical illness including lung disease requiring oxygen, Parkinson's disease, or a life-threatening illness with life expectancy less than six months.
  18. Allergy to beetroot juice
  19. Currently consuming one cup or more of beets daily. Participants will be asked to decrease beet consumption to less than one cup of beets per day for 14 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more for 30 days before the trial and during the trial, they will not be eligible for the clinical trial.
  20. Participation in or completion of a clinical trial in the previous three months, using investigator discretion for trials that may not impact study participation or outcome measures of the IMPACT PAD Trial.
  21. Visual impairment that limits walking ability.
  22. Unable to communicate in English, unless the participant communicates in Spanish and is enrolled at a site that can deliver the intervention in Spanish. All sites with a Spanish speaking coordinator and interventionist will be able to enroll Spanish-speaking participants. While investigators aim to be as inclusive as possible, resources are not available to allow inclusion of people speaking languages that are not Spanish or English.
  23. Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue.
  24. Planning to begin a supervised treadmill exercise program in the next 12 months.
  25. Heart attack or stroke in previous three months prior to baseline testing.
  26. An eGFR value <30 or potassium >5.0.
  27. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione fattoriale
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Home based exercise + nitrate rich beetroot juice

This group will be participating in home based exercise and drinking nitrate rich beetroot juice for six months.

This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention

Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.

Comparatore placebo: Home-based exercise + placebo

This group will be participating in home based exercise and drinking placebo beetroot juice with nitrate removed for six months.

This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention

Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.

Sperimentale: Attention control + nitrate-rich beetroot juice

This group will be participating in attention control and drinking nitrate rich beetroot juice for six months.

Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.

Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging "age pages" relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D.

Comparatore placebo: Attention control + placebo

This group will be participating in attention control and drinking placebo beetroot juice with nitrate removed for six months.

Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.

Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging "age pages" relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Six-Minute Walk Distance 6-month change
Lasso di tempo: Baseline to 6-month follow-up

Distance walked in six minutes

Baseline to 6-month follow-up

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Walking Impairment Questionnaire (WIQ) Distance Score 6-month change
Lasso di tempo: Baseline to 6-month follow-up.

Patient reported ability to walk long distances. Score Range 0-100, 100 is best.

Baseline to 6-month follow-up.
Walking Impairment Questionnaire (WIQ) Distance Score 12-month change
Lasso di tempo: Baseline to 12-month follow-up

Patient reported ability to walk long distances. Score Range 0-100, 100 is best.

Baseline to 12-month follow-up
PROMIS Mobility Questionnaire Score 6-month change
Lasso di tempo: Baseline to 6-month follow-up

Patient report of mobility in daily living. Score range is from zero to infinity and a higher score means a better outcome.

Baseline to 6-month follow-up
PROMIS Mobility Questionnaire Score 12-month change
Lasso di tempo: Baseline to 12-month follow-up.

Patient report of mobility in daily living. Score range is from zero to infinity and a higher score means a better outcome.

Baseline to 12-month follow-up.
Prevention of Hemodynamic Failure of The Revascularized Vessel
Lasso di tempo: Baseline to 12 month follow-up

Hemodynamic failure consists of loss of patency of the revascularized vessel. The outcome will be adjudicated as a categorical outcome. Medical records between randomization and final follow-up will be obtained and reviewed by the IMPACT PAD adjudication committee, consisting of field center investigators and an interventional cardiologist. Participants who meet pre-defined criteria for hemodynamic failure of the revascularized vessel.

Baseline to 12 month follow-up
Change in 6-minute walk distance
Lasso di tempo: 12 month follow-up

Change in 6-minute walk distance between baseline and 12-month follow-up

12 month follow-up

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Six-Minute Walk Distance
Lasso di tempo: Baseline to six-month follow-up at the time point that is twenty-four hours after the final study drink

Change in six-minute walk distance 24 hours after the final study beverage

Baseline to six-month follow-up at the time point that is twenty-four hours after the final study drink
Plasma Nitrite Levels
Lasso di tempo: Baseline to 6-month follow-up

Change in plasma nitrite levels in the blood at 6-month follow-up

Baseline to 6-month follow-up
BH4/BH2 6-month change
Lasso di tempo: Baseline to 6-month follow-up

Change in BH4/BH2 ratio

Baseline to 6-month follow-up
Progression of PAD
Lasso di tempo: Baseline to 12-month follow-up

Determine whether home-based walking exercise, compared to attention control prevents progression of PAD, defined by any new lower extremity revascularization, acute limb ischemia, or amputation of either lower extremity between baseline and 12-month follow-up.

Baseline to 12-month follow-up

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 agosto 2025

Completamento primario (Stimato)

1 febbraio 2032

Completamento dello studio (Stimato)

1 agosto 2032

Date di iscrizione allo studio

Primo inviato

8 novembre 2024

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2024

Primo Inserito (Effettivo)

13 novembre 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • STU00222333

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Periodo di condivisione IPD

Data will be available at the time the primary outcome manuscript is submitted for publication and will be available for up to 10 years.

Criteri di accesso alla condivisione IPD

Per BioLINCC

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .